Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Deadly attack on kindergarten reported in Sudan - 2Choosing Moving Styles for Your Restroom Redesign
- 3Congolese rape survivors search in vain for medicine after USAID cuts
- 4Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- 5All that You Really want to Be aware of Dental Inserts Facilities
- Instructions to Investigate Different Open Record Extra Offers Actually
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- Fundamental Home Machines for Improved Solace in Summer
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- Instructions to Pick the Right Senior Protection Plan.
- Mystery foot suggests a second early human relative lived alongside Lucy
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- What to know about the hepatitis B shot — and why Trump officials are targeting it
